Cathie Wood’s Top Picks: CRISPR Therapeutics and Spotify Show Strong Performance

Ark Invest CEO Cathie Wood, often a divisive figure in investment circles, has seen mixed long-term results with her actively managed ETFs. Yet two of her selections—CRISPR Therapeutics and Spotify—have delivered exceptional returns this fiscal year, with CRISPR's stock surging 85% year-to-date.

CRISPR Therapeutics, a gene-editing biotech, is gaining momentum with its CTX310 program targeting LDL cholesterol and triglycerides. Early clinical data shows promise for addressing cardiovascular conditions affecting 40 million Americans. The company's pipeline progress mirrors the explosive potential seen in high-growth crypto assets.

While no cryptocurrencies were mentioned in the original report, the growth trajectory of these stocks parallels the asymmetric upside potential of emerging digital assets. Institutional investors tracking Wood's moves might consider how similar volatility/reward profiles appear in altcoins like METIS or SAGA—projects combining technological innovation with speculative fervor.